Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABP 501-HCF · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment A: ABP 501-HCF | EXPERIMENTAL | Participants will be administered a single SC dose of ABP 501-HCF on Day 1. |
| Treatment B: ABP 501-LCF | EXPERIMENTAL | Participants will be administered a single SC dose of ABP 501-LCF on Day 1. |
| Name | Type | Description |
|---|---|---|
| ABP 501-HCF | DRUG | Participants will receive a single-dose SC injection of ABP 501-HCF. |
| ABP 501-LCF | DRUG | Participants will receive a single-dose SC injection of ABP 501-LCF |
Inclusion Criteria: * Participants must sign an Institutional Review Board/Independent Ethics Committee (IRB/IEC) approved informed consent form (ICF) before any study-specific procedures are performed. * Healthy adult male or female participants between 18 and 55 years of age, inclusive, at the ti...
ABP 501-HCF is an investigational small molecule being developed for adalimumab, which is an immunology condition. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
ABP 501-HCF is being developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol AMGN.
ABP 501-HCF is in Phase 1 clinical development. It is an investigational drug and has not been approved for commercial use.
ABP 501-HCF has one completed Phase 1 trial, NCT05909852, which compared its pharmacokinetics with another formulation in healthy adult participants. The trial enrolled 372 participants in the United States.
ABP 501-HCF and ABP 501-LCF are different formulations of the same drug, ABP 501. The HCF version is 40 mg/0.4 mL, while the LCF version is 40 mg/0.8 mL, and they were compared in a clinical trial.